Guggenheim raised the firm’s price target on AbbVie (ABBV) to $242 from $227 and keeps a Buy rating on the shares after updating the firm’s model ahead of the company’s Q3 earnings release due on October 31. The firm believes investors continue to view AbbVie as “a relatively easy story to support” given the solid visibility the company has on its topline and bottom line growth outlook, the analyst says in a preview.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie completes acquisition of Gilgamesh Pharmaceuticals’ bretisilocin
- AbbVie price target raised to $250 from $236 at Raymond James
- 3 Best Dividend Aristocrat Stocks to Buy Now, 10/16/2025
- AbbVie’s Phase 2 Study on CLL/SLL Treatment: Key Updates and Market Impact
- AbbVie’s Venetoclax Study Completion: A Potential Boost for Investors